Role of Genetic Polymorphisms in Hepatitis C Virus Chronic Infection

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2015 Sep 19

PMID 26380828

Citations 10

Authors

Nicola Coppola

Mariantonietta Pisaturo

Caterina Sagnelli

Lorenzo Onorato

Evangelista Sagnelli

Affiliations

Soon will be listed here.

Abstract

Aim: To analyze the host genetics factors influencing the clinical course and the response to antiviral treatment in patients with chronic hepatitis C (CHC).

Methods: We conducted an electronic search on the PubMed and MEDLINE (2000-2014) databases and Cochrane library (2000-2014). A total of 73 articles were retrieved and their data were extensively evaluated and discussed by the authors and then analyzed in this review article.

Results: Several studies associated polymorphisms in the interleukin 28B gene on chromosome 19 (19q13.13) with a spontaneous viral clearance in acute hepatitis C and with the response to pegylated interferon (Peg-IFN)-based treatment in chronic hepatitis C patients. Other investigations demonstrated that inosine triphosphate pyrophosphatase genetic variants protect hepatitis C virus-genotype-1 CHC patients from ribavirin-induced anemia, and other studies that a polymorphism in the patatin-like phospholipase domain-containing protein 3 was associated with hepatic steatosis in CHC patients. Although not conclusive, some investigations suggested that the vitamin D-associated polymorphisms play an important role in the achievement of sustained virologic response in CHC patients treated with Peg-IFN-based antiviral therapy. Several other polymorphisms have been investigated to ascertain their possible impact on the natural history and on the response to treatment in patients with CHC, but the data are preliminary and warrant confirmation.

Conclusion: Several genetic polymorphisms seem to influence the clinical course and the response to antiviral treatment in patients with CHC, suggesting individualized follow up and treatment strategies.

Citing Articles

Toll-like receptor 7 and RIG-I-like receptors expression in peripheral blood mononuclear cells of naïve patients with hepatitis C.

Gilanipour A, Teimoori A, Arabzadeh S, Mollaie H, Mousavi E BMC Res Notes. 2023; 16(1):344.

PMID: 37993939 PMC: 10664272. DOI: 10.1186/s13104-023-06626-2.

HCV treatment outcome depends on SNPs of IFNL3-Gene polymorphisms (rs12979860) and cirrhotic changes in liver parenchyma.

Abd Alla M, Dawood R, Rashed H, El-Dessouky Y, AbuFarrag G, Ammar I Heliyon. 2023; 9(11):e21194.

PMID: 37928048 PMC: 10623284. DOI: 10.1016/j.heliyon.2023.e21194.

Recognition of 7 genes signature (Cirrhosis Risk Score) in the diagnosed non-responders to DAAs therapy by intra-PBMCs nested HCV RNA PCR.

Galal A, Dawood R, El Awady M, El-Dessouky Y, Mahmoud M, Abd Alla M J Genet Eng Biotechnol. 2023; 21(1):89.

PMID: 37646837 PMC: 10468448. DOI: 10.1186/s43141-023-00544-3.

The role of vitamin D receptor polymorphisms in the course of chronic hepatitis C infection.

Tsounis E, Tourkochristou E, Sapsani A, Aggeletopoulou I, Lourida T, Zisimopoulos K Ann Gastroenterol. 2022; 35(2):203-212.

PMID: 35479594 PMC: 8922255. DOI: 10.20524/aog.2022.0697.

Impact of , , , and Gene Polymorphisms on the Severity of Liver Fibrosis Induced by HCV Genotype 4.

Hemeda A, Ahmad Mohamed A, Aziz R, Abdel-Hakeem M, Ali-Tammam M Viruses. 2021; 13(4).

PMID: 33924242 PMC: 8074775. DOI: 10.3390/v13040714.

References

Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder J . The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000; 288(5464):339-44. DOI: 10.1126/science.288.5464.339. View

Rangnekar A, Fontana R . Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther. 2012; 36(2):104-14. DOI: 10.1111/j.1365-2036.2012.05145.x. View

Firdaus R, Biswas A, Saha K, Mukherjee A, Chaudhuri S, Chandra A . Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. PLoS One. 2014; 9(6):e99126. PMC: 4051780. DOI: 10.1371/journal.pone.0099126. View

McHutchison J, Manns M, Patel K, Poynard T, Lindsay K, Trepo C . Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123(4):1061-9. DOI: 10.1053/gast.2002.35950. View

Boglione L, Cusato J, De Nicolo A, Cariti G, Allegra S, Ghisetti V . Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. Antiviral Res. 2014; 106:105-10. DOI: 10.1016/j.antiviral.2014.03.016. View

Chuang W, Yu M . Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol. 2012; 48(1):22-30. PMC: 3698435. DOI: 10.1007/s00535-012-0669-x. View

Post J, Ratnarajah S, Lloyd A . Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci. 2008; 66(5):733-56. PMC: 11131471. DOI: 10.1007/s00018-008-8270-4. View

Norgaard Eskesen A, Melum E, Moghaddam A, Bjoro K, Verbaan H, Ring-Larsen H . Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eur J Gastroenterol Hepatol. 2012; 24(8):890-6. DOI: 10.1097/MEG.0b013e3283546efd. View

. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55(2):245-64. DOI: 10.1016/j.jhep.2011.02.023. View

10.

Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

11.

Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R . Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002; 37(6):837-42. DOI: 10.1016/s0168-8278(02)00299-4. View

12.

Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S . Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology. 2012; 56(5):1641-50. DOI: 10.1002/hep.25848. View

13.

Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V . Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol. 2005; 42(5):646-51. DOI: 10.1016/j.jhep.2004.12.027. View

14.

Poordad F, Lawitz E, Kowdley K, Cohen D, Podsadecki T, Siggelkow S . Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013; 368(1):45-53. DOI: 10.1056/NEJMoa1208809. View

15.

Coppola N, Zampino R, Sagnelli C, Bellini G, Marrone A, Stanzione M . Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C. PLoS One. 2014; 9(6):e99450. PMC: 4062424. DOI: 10.1371/journal.pone.0099450. View

16.

Tillmann H, Thompson A, Patel K, Wiese M, Tenckhoff H, Nischalke H . A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010; 139(5):1586-92, 1592.e1. DOI: 10.1053/j.gastro.2010.07.005. View

17.

Rau M, Stickel F, Russmann S, Manser C, Becker P, Weisskopf M . Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J Hepatol. 2012; 58(4):669-75. DOI: 10.1016/j.jhep.2012.11.027. View

18.

Ghany M, Strader D, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-74. PMC: 7477893. DOI: 10.1002/hep.22759. View

19.

Sulkowski M, Gardiner D, Rodriguez-Torres M, Reddy K, Hassanein T, Jacobson I . Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370(3):211-21. DOI: 10.1056/NEJMoa1306218. View

20.

Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S . IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2010; 54(4):716-22. DOI: 10.1016/j.jhep.2010.07.019. View